In last trading session, Novavax, Inc. (NASDAQ:NVAX) saw 9.84 million shares changing hands with its beta currently measuring 2.04. Company’s recent per share price level of $10.35 trading at $0.2 or 1.97% at ring of the bell on the day assigns it a market valuation of $1.66B. That closing price of NVAX’s stock is at a discount of -130.53% from its 52-week high price of $23.86 and is indicating a premium of 65.89% from its 52-week low price of $3.53. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 8.3 million shares which gives us an average trading volume of 6.84 million if we extend that period to 3-months.
For Novavax, Inc. (NVAX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.60. Splitting up the data highlights that, out of 16 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 6 suggested the stock as a Hold whereas 10 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.82 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Novavax, Inc. (NASDAQ:NVAX) trade information
Upright in the green during last session for gaining 1.97%, in the last five days NVAX remained trading in the red while hitting it’s week-highest on Monday, 10/14/24 when the stock touched $10.35 price level, adding 22.41% to its value on the day. Novavax, Inc.’s shares saw a change of 115.62% in year-to-date performance and have moved -19.80% in past 5-day. Novavax, Inc. (NASDAQ:NVAX) showed a performance of -17.60% in past 30-days. Number of shares sold short was 33.88 million shares which calculate 5.19 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 22 to the stock, which implies a rise of 52.95% to its current value. Analysts have been projecting 14 as a low price target for the stock while placing it at a high target of 174. It follows that stock’s current price would drop -35.27% in reaching the projected high whereas dropping to the targeted low would mean a loss of -35.27% for stock’s current value.
Novavax, Inc. (NVAX) estimates and forecasts
Statistics highlight that Novavax, Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company added 166.07% of value to its shares in past 6 months, showing an annual growth rate of 83.36% while that of industry is 17.50. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -22.60% from the last financial year’s standing.
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 72.02M for the same. And 4 analysts are in estimates of company making revenue of 192.07M in the next quarter. Company posted 186.99M and 291.34M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 11.55% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 81.38% while estimates for its earnings growth in next 5 years are of 37.90%.
Novavax, Inc. (NASDAQ:NVAX)’s Major holders
Insiders are in possession of 4.38% of company’s total shares while institution are holding 54.15 percent of that, with stock having share float percentage of 56.63%. Investors also watch the number of corporate investors in a company very closely, which is 54.15% institutions for Novavax, Inc. that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at NVAX for having 14.08 million shares of worth $178.19 million. And as of 2024-06-30, it was holding 10.0599 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 11.85 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.4669 of outstanding shares, having a total worth of $149.98 million.
